One extra radiation dose after standard brain cancer therapy: can it boost the immune system?
NCT ID NCT07831772
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers at the University of Minnesota are testing whether a single extra dose of radiation, given about four weeks after standard chemotherapy, is safe and practical for adults with newly diagnosed glioblastoma. Participants first receive standard surgery, radiation, and chemotherapy, then receive one additional radiation treatment directed at the area where the tumor was removed. The study will track whether patients complete the extra dose and whether it causes serious side effects. Blood samples will also be checked to see how the extra radiation affects certain immune cells.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a single extra dose of radiation to the brain after standard treatment
- What this could lead to
- If it works, this could offer a practical way to add one more radiation dose after standard glioblastoma treatment, possibly helping the immune system fight the tumor.
- What could go wrong
- This is a very small feasibility study with only 4 participants, so it cannot prove the treatment works or extends life. The extra radiation may cause serious side effects, and the immune cell changes may not translate into any benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 4 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed diagnosis of glioblastoma according to WHO classification criteria for which standard-of-care surgical resection, concurrent temozolomide and radiotherapy, and adjuvant temozolomide is planned * Planning to receive standard-of-care radiotherapy with a biological effective dose of 60 Gy or less in 30 fractions * Age 18 years or older at the time of consent * Karnofsky performance status of 70 or higher * Life expectancy of 3 months or longer * Adequate organ function confirmed by laboratory values obtained within 14 days of study enrollment, defined as absolute neutrophil count at least 1.5 × 10\^9/L, platelets at least 50 × 10\^9/L, and hemoglobin at least 8 g/dL independent of transfusion within 14 days of screening * Persons of childbearing potential or with partners of childbearing potential must be willing to use contraception during study treatment * Concurrent use of other investigative treatment is permitted * Voluntary written consent prior to the performance of any research-related activity Exclusion Criteria: * Pregnant or breastfeeding * Presence of brain stem involvement within the planning target volume from the initial course of standard-of-care radiotherapy * Prior radiation therapy to the brain * Contraindication to MRI or CT * Uncontrolled intercurrent illness, including ongoing or active infection, hypertension, serious cardiac arrhythmia requiring medication, acute cardiovascular disease or clinically manifested myocardial insufficiency, or psychiatric illness or social situations that would limit compliance with study requirements * Any medical condition or clinical laboratory abnormality that, in the investigator's judgment, precludes safe participation in and completion of the study or could affect compliance with protocol conduct or interpretation of results
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain tumor are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Minnesota Radiation Oncology
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a trio of repurposed drugs shrink recurrent brain tumors?
- Can an existing drug boost bevacizumab against recurrent brain cancer?
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients
- Breathing CO2 during brain scans could reveal hidden tumor disruption